An observational study in Lung Transplantation, sponsored by University of Turin, Italy. Status unknown at 1 site in Italy. Per ClinicalTrials.gov, last updated 2016-02-01.
Sponsored by University of Turin, Italy · Observational
Ex vivo lung perfusion (EVLP) is an established strategy to evaluate and optimize high-risk donor lungs that would otherwise be rejected for transplantation mainly due to the presence of edema or infection. Extracorporeal circuits may negatively affects pharmacokinetic (PK) of several drugs including antibiotics, thus exposing patients to risk of therapeutic failure or drug toxicity. The investigators set out to examine the concentration of imipenem in lung perfusate and in lung biopsy during EVLP, and its clinical impact.
University of Turin, Italy is the lead sponsor of 206 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
lungs from brain dead donors that were considered at high-risk for transplantation and underwent EVLP
Exclusion Criteria:
All lungs from brain dead donors that were considered at high-risk for transplantation and underwent EVLP in the Turin lung transplantation program
Procedure: normothermic ex vivo lung perfusion
imipenem concentration
concentration of imipenem in lung perfusate and in lung biopsy during EVLP
Time frame: change from baseline in imipenem concentration at 6 hours
pathogens isolated from donors
Time frame: 48 hours before lung procurement
pathogens isolated from recipients
Time frame: 48 hours after lung transplantation
Clinical Pulmonary Infection Score
Time frame: at 72 hours after lung transplantation
Primary graft dysfunction
Time frame: at 72 hours after lung transplantation
Days of mechanical ventilation
Time frame: at 28 days
Intensive Care Unit length of stay
Time frame: at day 28
This study is status unknown, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Turin, Italy